Danaher stock
Price history
+5.34% over the period1 year: from $221.20 (November 13, 2025) to $233.02 (November 13, 2026), +5.34%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 13, 2026 | $233.02 |
| October 30, 2026 | $232.23 |
| September 30, 2026 | $221.55 |
| August 31, 2026 | $213.56 |
| July 31, 2026 | $194.98 |
| June 30, 2026 | $190.48 |
| May 29, 2026 | $182.67 |
| April 30, 2026 | $178.95 |
| March 31, 2026 | $189.60 |
| February 27, 2026 | $210.64 |
| January 30, 2026 | $218.89 |
| December 31, 2025 | $228.92 |
| November 28, 2025 | $226.78 |
| November 13, 2025 | $221.20 |
At a glance
The company
Designs and manufactures professional, medical, research and industrial products and services for biotechnology, life sciences and diagnostics markets
Latest results
Quarter to September 30, 2026 · EPS $2.11 (estimate $1.91)
Next event
TickerLandia's take on Danaher
- Pricier than usual relative to earnings: P/E on the latest fiscal year 46 vs a median of 34 over its last 10 fiscal years.
- Priced in line with similar companies: trailing 12-month P/E 39 vs 36 (+6%) in a group of 10.
- Strong point: Market momentum (75/100 in its group). Weak point: Growth (44/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−4.03% from the 52-week high
Analysts · 24 analysts
Average target$259.90+11.54% vs. price
Buy 20 · Hold 4 · Sell 0 · Strong buy
TickerLandia Fingerprint: Danaher
Compared with similar companies: strong momentum.
Financials and price compared with 27 companies in the diagnostics & research industry, worldwide. Momentum and risk compared with 883 North American stocks.
Priceaverage56
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 38.6 69 Forward P/E 25.0 54 Price/book 3.06 37 EV/EBITDA 22.5 62 Price/sales 6.40 57 Profitabilityaverage53
How much it earns on revenue and capital.
Metric Value Position in group Gross margin 59.4% 69 Operating margin 22.0% 69 Net margin 16.9% 69 ROE 8.2% 31 ROA 4.1% 28 Earnings stabilityaverage50
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 3.8% 39 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 61 Growthaverage44
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) −2.67% 13 Earnings growth (year over year) +37.80% 74 Revenue growth (year over year) +8.30% 46 Financial strengthaverage57
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Interest coverage 20.3 83 Net debt/EBITDAcounts in reverse: lower means more financial strength 1.93 46 Debt/equitycounts in reverse: lower means more financial strength 0.52 57 Current ratio 1.63 43 Dividendaverage56
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years 34 years 91 Dividend yield 0.7% 30 Payout ratio 25.2% 47 Market momentumstrong75
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +17.87% 88 1-year return +5.34% 38 Relative strength (6 months) +38.20% 90 Distance from 200-day average +15.93% 83 Riskaverage45
How much the price swings.
Metric Value Position in group Maximum drawdown (12 months) 33.1% 60 Volatility (60 days) 27.5% 32 Beta (1 year) 0.56 43
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Danaher is pricier than in the past and pricier than similar companies
On the latest fiscal year's earnings (2025), Danaher's P/E today is 46.1, above the median of its last 10 fiscal years (33.7; between 18.9 and 45.3 from 2016 to 2025). Danaher's P/E (trailing 12 months): 38.6, +6% against the median of a group of 10 similar companies (36.5).
Compared with 10 similar companies
| Metric | Danaher | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 38.6 | High | |
| Forward P/E | 25.0 | Middle | |
| Operating margin | 22.0% | Middle | |
| ROE | 8.2% | Middle | |
| Debt/equity | 0.52 | Low |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Danaher. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$6.55B
Latest quarter · Q3 2026
Net income
$1.24B
Latest quarter · Q3 2026
Quarterly net margin
18.8%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- $163.94B
- P/E
- 38.6
- EPS
- $6.04
- Volume
- 3.34M
- Daily trading
- €865.44M
- Dividend yield
- 0.65%
- Last ex-dividend on September 30, 2026
How Danaher is changing
All resultsRevenue grew 2.0% a year on average over the last 5 years
Operating margin fell from 28.3% to 19.1%
Profits turn into cash: free cash flow equal to 133% of net income
Returns
Danaher returns with dividends
$1,000 invested in Danaher 5 years ago, on November 15, 2021, would be worth $901 today with dividends reinvested: −9.95% in total, −2.08% per year. On price alone it would be $877 (−12.29%).
| Period | Danaher | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | +4.57% | −3.12% | $1,046 |
| 6 months | +40.38% | +1.58% | $1,404 |
| Year to date | +1.79% | +10.46% | $1,018 |
| 1 year | +6.13% | +12.23% | $1,061 |
| 3 years | +21.02% | +71.41% | $1,210 |
| 5 years | −9.95% | +61.48% | $901 |
| 10 years | +250.02% | +249.40% | $3,500 |
Over the last 6 months it has done better than 78% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. S&P 500: price only. Calculate your investment
The chart in detail
Danaher: technical analysis
Danaher shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 20.9% below its highest close since January 2, 1990 ($294.71, September 3, 2021).
- Trend
- No clear trend
- RSI (14 sessions)
- 55
- Between 30 and 70
- vs 200-session average
- +15.93%
Active signals
The price is moving in an unusually narrow range compared with the last year.
since November 10, 2026
Support and resistance
Price areas where Danaher has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance$238.30+2.26%2 touches, last on October 30, 2026
- Last price$233.02
- Support$232.59−0.19%2 touches, last on December 12, 2025
- Support$227.92−2.19%3 touches, last on September 28, 2026
- Support$222.79−4.39%2 touches, last on November 6, 2026
Volatility and risk
Over the last year it has moved less than the S&P 500.
- Beta (1 year) vs S&P 500
- 0.56
- Volatility (60 sessions, annualised)
- 27.5%
- Largest fall in the last year
- −33.11%
Close of November 13, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Danaher: seasonality
Average monthly price change over 37 years
Over the last 37 years, the strongest month for Danaher has been November: +3.56% on average, positive in 27 years out of 36. The weakest has been September: −1.89% on average, positive in 15 years out of 37.
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +0.43% | −0.30% | 16 of 36 |
| February | +0.51% | +0.61% | 19 of 37 |
| March | +2.26% | +1.69% | 24 of 37 |
| April | +2.81% | +1.99% | 22 of 37 |
| May | +1.54% | +1.66% | 24 of 37 |
| June | +0.69% | +1.47% | 23 of 37 |
| July | +3.43% | +3.48% | 26 of 37 |
| August | −0.03% | +1.44% | 22 of 37 |
| September | −1.89% | −0.76% | 15 of 37 |
| October | +2.91% | +2.41% | 23 of 37 |
| November | +3.56% | +3.28% | 27 of 36 |
| December | +2.94% | +2.70% | 25 of 36 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Danaher and its competitors
Hospitals, physicians' offices, reference laboratories and other critical care settings are among the customers for the company's clinical instruments, consumables, software and services, which are used to diagnose disease and support treatment decisions. Companies developing and manufacturing therapeutics buy its cell culture media, filtration technologies, chromatography resins, single-use hardware and manufacturing suite design services.
- Headquarters
- Washington, United States
- Employees
- 58,000
- Founded
- 1969
- Chief executive
- Julie Montgomery
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| DanaherDHR | $163.94B | 22.0% | 38.6 | +40.38% |
| Thermo Fisher ScientificTMO | $259.44B | 19.1% | 36.9 | +56.99% |
| WatersWAT | $90.45B | 16.0% | 192.6 | +37.42% |
| IDEXX LaboratoriesIDXX | $55.48B | 32.5% | 47.0 | +33.21% |
| Agilent TechnologiesA | $49.04B | 24.5% | 34.3 | +54.30% |
| NateraNTRA | $46.27B | -8.5% | — | +63.37% |
Same industry or related industries, similar size. Compare Danaher with its competitors · Full profile
